Cargando…

Tocilizumab in patients infected by SARS-CoV2()

Detalles Bibliográficos
Autores principales:	Sancho, Milagros, Muñiz, Javier, Cardinal-Fernández, Pablo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier España, S.L.U. 2021
Materias:	Special Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7972641/ https://www.ncbi.nlm.nih.gov/pubmed/33763598 http://dx.doi.org/10.1016/j.medcle.2020.12.010

Ejemplares similares

Tocilizumab en el paciente con COVID-19
por: Sancho, Milagros, et al.
Publicado: (2021)

Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab()
por: Figuero-Pérez, Luis, et al.
Publicado: (2021)

Compassionate use of tocilizumab in severe SARS-CoV2 pneumonia
por: Górgolas Hernández-Mora, Miguel, et al.
Publicado: (2021)

Tocilizumab reduces the risk of ICU admission and mortality in patients with SARS-CoV-2 infection
por: Moreno-García, Estela, et al.
Publicado: (2021)

SARS-CoV-2 and Chlamydia pneumoniae co-infection: A review of the literature
por: Frutos, María Celia, et al.
Publicado: (2022)

The interplay of SARS-CoV-2 and Clostridioides difficile infection
por: Khanna, Sahil, et al.
Publicado: (2021)

Transmission and clinical characteristics of asymptomatic patients with SARS-CoV-2 infection
por: Tan, Jie, et al.
Publicado: (2020)

Is there any effect of flu vaccine on the SARS-CoV-2 infected patients?
por: El-Qutob, D., et al.
Publicado: (2022)

Is there any effect of flu vaccine on the SARS-CoV-2 infected patients?
por: El-Qutob, D., et al.
Publicado: (2022)

Combined therapy of tocilizumab and corticosteroids in severe SARS-CoV-2 disease()
por: González-Castro, A., et al.
Publicado: (2022)

Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS‐CoV‐2
por: Petrak, Russell M., et al.
Publicado: (2021)

Early outcomes in adults hospitalized with severe SARS-CoV-2 infection receiving tocilizumab
por: Sánchez-Montalvá, Adrián, et al.
Publicado: (2022)

Early outcomes in adults hospitalized with severe SARS-CoV-2 infection receiving tocilizumab
por: Sánchez-Montalvá, Adrián, et al.
Publicado: (2022)

Cardiovascular disease in SARS‐CoV‐2 infection
por: Sato, Kei, et al.
Publicado: (2021)

Use of the rheumatic drug tocilizumab for treatment of SARS-CoV-2 patients
por: Grygiel-Górniak, Bogna, et al.
Publicado: (2021)

Myocarditis related SARS-CoV-2 infection or vaccination: an expert consensus statement on its diagnosis and management
por: Barreiro-Pérez, Manuel, et al.
Publicado: (2023)

SARS-CoV-2 Variants and Vaccines
por: Krause, Philip R., et al.
Publicado: (2021)

Inflammation, malnutrition, and SARS-CoV-2 infection: A disastrous combination()
por: Carretero Gómez, J., et al.
Publicado: (2020)

Posterior Reversible Encephalopathy Syndrome in a Patient With SARS-CoV-2 Infection Treated With Tocilizumab
por: Talluri, Krishna, et al.
Publicado: (2021)

Case Report: Tocilizumab for the Treatment of SARS-CoV-2 Infection in a Patient With Aplastic Anemia
por: Keiffer, Gina, et al.
Publicado: (2020)

Recommendations on the management of adult patients with rheumatic diseases in the context of SARS-CoV-2/COVID-19 infection. Colombian Association of Rheumatology()
por: Saldarriaga Rivera, Lina María, et al.
Publicado: (2020)

Tocilizumab or glucocorticoids treatment for patients with SARS-CoV-2 pneumonia: An observational study
por: Dolci, Giovanni, et al.
Publicado: (2021)

Therapeutische Nanobodies gegen SARS-CoV-2
por: Güttler, Thomas, et al.
Publicado: (2022)

Air contamination with SARS-CoV-2 in the operating room
por: Hirota, Kazuyoshi
Publicado: (2020)

Tocilizumab therapy in SARS-CoV-2 pneumonia: A matched retrospective cohort analysis
por: Fernández-Ruiz, Mario, et al.
Publicado: (2022)

Tocilizumab therapy in SARS-CoV-2 pneumonia: A matched retrospective cohort analysis
por: Fernández-Ruiz, Mario, et al.
Publicado: (2022)

Development and validation of a prediction model for tocilizumab failure in hospitalized patients with SARS-CoV-2 infection
por: Mussini, Cristina, et al.
Publicado: (2021)

Outcomes of SARS‐CoV‐2 Infections in Patients with Neurodegenerative Diseases in the LEOSS Cohort
por: Huber, Meret K., et al.
Publicado: (2021)

Rapid antigen tests for the detection of SARS-CoV-2: A narrative review
por: Aguilar-Shea, Antonio L., et al.
Publicado: (2021)

SARS-CoV-2: what it is, how it acts, and how it manifests in imaging studies()
por: Fernández-Pérez, G.C., et al.
Publicado: (2021)

Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment
por: Masuccio, Fabio Giuseppe, et al.
Publicado: (2020)

Therapeutic Efficacy and Outcomes of Remdesivir versus Remdesivir with Tocilizumab in Severe SARS-CoV-2 Infection
por: Vulturar, Damiana-Maria, et al.
Publicado: (2022)

Interpretation of laboratory tests for prevention of the SARS-CoV-2 transmission
por: Masui, Kenichi
Publicado: (2020)

Control of SARS-CoV-2 transmission in orthodontic practice
por: Guo, Yongwen, et al.
Publicado: (2020)

The potential association between PARP14 and the SARS-CoV-2 infection (COVID-19)
por: Tauber, Amanda L, et al.
Publicado: (2021)

(18)F-FDG-PET/CT in SARS-CoV-2 infection and its sequelae()
por: Rodríguez-Alfonso, B., et al.
Publicado: (2021)

Are hemoglobin-derived peptides involved in the neuropsychiatric symptoms caused by SARS-CoV-2 infection?
por: Mendonça, Michelle Mendanha, et al.
Publicado: (2022)

Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation()
por: Aomar-Millán, Ismael Francisco, et al.
Publicado: (2021)

The Use of Single Therapy With Tocilizumab Versus Combination Therapy With Remdesivir and Tocilizumab in SARS-CoV-2 Patients in El Paso, Texas
por: Almaghlouth, Nouf K, et al.
Publicado: (2021)

550. Clinical impact of Tocilizumab therapy in SARS-CoV-2 respiratory infections in ICU and non-ICU patients
por: Vyas, Nikunj M, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0dudg8cod7e5pjpml2o26ssgq6